Apoptotic effects of norfloxacin on corneal endothelial cells.
Animals
Anti-Bacterial Agents
/ pharmacology
Apoptosis
/ drug effects
Cats
Cell Cycle
/ drug effects
Cell Line
Cell Survival
/ drug effects
Cornea
/ cytology
DNA Fragmentation
Endothelial Cells
/ drug effects
Humans
Male
Membrane Potential, Mitochondrial
/ drug effects
Microscopy, Electron, Transmission
Norfloxacin
/ pharmacology
Apoptosis
Corneal endothelial cells
Death receptor-mediated apoptotic signaling pathway
Mitochondrion-dependent apoptotic signaling pathway
Norfloxacin
Toxicity
Journal
Naunyn-Schmiedeberg's archives of pharmacology
ISSN: 1432-1912
Titre abrégé: Naunyn Schmiedebergs Arch Pharmacol
Pays: Germany
ID NLM: 0326264
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
22
05
2019
accepted:
07
08
2019
pubmed:
20
8
2019
medline:
1
1
2021
entrez:
18
8
2019
Statut:
ppublish
Résumé
Norfloxacin, a frequently used ocular antibiotic, might have cytotoxic effect on human corneal endothelial cells (HCECs), subsequently damage the cornea and finally impair human vision. However, the possible mechanisms of cytotoxicity of norfloxacin to HCEC line are unclear. Herein, we investigated the cytotoxicity of norfloxacin and its underlying cellular and molecular mechanisms using in vitro cultured non-transfected HCECs and verified the cytotoxicity with cat corneal endothelium in vivo. In the present study, the cytotoxicity of norfloxacin in the in vitro cultured HCECs was recognized by causing abnormal morphology such as cell shrinkage and detachment from plate bottom, and decline of viability of in vitro cultured HCECs. Then, its cytotoxicity was verified by inducing reduction of cell density and morphological abnormality of in vivo cat corneal endothelial cells. Furthermore, the cytotoxicity of norfloxacin in HCECs was corroborated as apoptosis by elevation of plasma membrane permeability, S phase arrest, phosphatidylserine externalization, DNA fragmentation, and apoptotic body formation in in vitro cultured HCECs and apoptosis-like swollen cells in the in vivo model. Moreover, norfloxacin induced extrinsic death receptor-mediated apoptosis pathway by activating caspase-2/-8/-3 and intrinsic mitochondrion-dependent apoptosis pathway by downregulating anti-apoptotic Bcl-2 and upregulating of pro-apoptotic Bad, which disrupted mitochondrial transmembrane potential, subsequently upregulated cytoplasmic cytochrome c and apoptosis-inducing factor and finally activated caspase-9/-3. Generally, norfloxacin induces HCE cell apoptosis via a death receptor-mediated and mitochondrion-dependent signaling pathway.
Identifiants
pubmed: 31420720
doi: 10.1007/s00210-019-01711-5
pii: 10.1007/s00210-019-01711-5
doi:
Substances chimiques
Anti-Bacterial Agents
0
Norfloxacin
N0F8P22L1P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
77-88Références
Immunity. 2019 Jun 18;50(6):1352-1364
pubmed: 31216460
J Immunol. 1999 Jun 1;162(11):6534-42
pubmed: 10352269
Mol Vis. 2013;19:400-7
pubmed: 23441111
Prog Retin Eye Res. 2003 May;22(3):359-89
pubmed: 12852491
J Biol Chem. 2001 Jan 12;276(2):1071-7
pubmed: 10986279
Cell Health Cytoskelet. 2012 Feb 1;2012(4):11-27
pubmed: 22593641
J Toxicol Sci. 2015 Aug;40(4):427-36
pubmed: 26165639
Biochim Biophys Acta Mol Cell Res. 2019 Apr;1866(4):575-587
pubmed: 30594496
Eur J Clin Pharmacol. 1997;53(3-4):251-5
pubmed: 9476040
Curr Med Res Opin. 2008 Feb;24(2):419-24
pubmed: 18157922
Cell Death Differ. 2006 Sep;13(9):1423-33
pubmed: 16676004
Basic Clin Pharmacol Toxicol. 2013 Nov;113(5):329-38
pubmed: 23826964
Biocontrol Sci. 2012 Jun;17(2):93-9
pubmed: 22790846
Exp Biol Med (Maywood). 2016 Jul;241(13):1457-65
pubmed: 27022135
Trends Cell Biol. 2018 Jun;28(6):475-493
pubmed: 29551258
Int J Biol Macromol. 2019 Sep 1;136:1237-1246
pubmed: 31252007
Cancer Biol Ther. 2005 Feb;4(2):139-63
pubmed: 15725726
Biochem Pharmacol. 2019 Apr;162:250-261
pubmed: 30668936
Science. 1997 Feb 21;275(5303):1132-6
pubmed: 9027315
Adv Cancer Res. 2012;116:165-97
pubmed: 23088871
Nat Rev Mol Cell Biol. 2014 Jan;15(1):49-63
pubmed: 24355989
Toxicol Sci. 2017 Mar 1;156(1):252-260
pubmed: 28115640
Acta Biochim Biophys Sin (Shanghai). 2005 Nov;37(11):719-27
pubmed: 16270150
Clin Exp Ophthalmol. 2008 Aug;36(6):553-9
pubmed: 18954319
Cell Cycle. 2013 Apr 1;12(7):1091-104
pubmed: 23462184
Int J Biochem Cell Biol. 2004 Dec;36(12):2463-72
pubmed: 15325585
Biocontrol Sci. 2010 Sep;15(3):97-102
pubmed: 20938094
Drug Chem Toxicol. 2015 Jan;38(1):16-21
pubmed: 24641202
J Neurosci Methods. 2000 Mar 15;96(2):147-52
pubmed: 10720679
Pharm Biol. 2016;54(3):503-8
pubmed: 26030464
Biochim Biophys Acta. 1998 Aug 10;1366(1-2):139-49
pubmed: 9714780
Exp Eye Res. 2010 Sep;91(3):326-35
pubmed: 20599432
Exp Toxicol Pathol. 2015 Oct;67(10):517-24
pubmed: 26296992
Hum Exp Toxicol. 2017 Aug;36(8):765-775
pubmed: 27590991
Graefes Arch Clin Exp Ophthalmol. 1999 Feb;237(2):89-92
pubmed: 9987622
Toxicol In Vitro. 2016 Sep;35:36-42
pubmed: 27216471
Mol Vis. 2011 Feb 15;17:469-80
pubmed: 21365020
Int J Ophthalmol. 2014 Feb 18;7(1):14-21
pubmed: 24634857
Trends Cell Biol. 2019 Apr;29(4):323-338
pubmed: 30665736
Methods Mol Biol. 2004;285:105-11
pubmed: 15269403
Basic Clin Pharmacol Toxicol. 2014 Apr;114(4):352-9
pubmed: 24373304
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14681-6
pubmed: 9843949